Paclitaxel eluting stents for the treatment of angiographically non-significant atherosclerotic lesions.
OBJECTIVE
To assess the safety and efficacy of the implantation of Paclitaxel Eluting Stents (PES) for de novo, non-flow limiting lesions.


RESULTS
We assessed the 12-month occurrence of major adverse cardiac events (MACE) in 21 patients (4% of the total population treated in a 'real world' registry) with 22 non-significant coronary narrowings treated with PES. The following criteria had to be met: (1) the lesion was de novo; (2) the location was non-ostial, and not a bifurcation lesion; (3) the diameter stenosis by quantitative coronary angiography (QCA) was <50%; (4) there was no visible thrombus and (5) the lesion was not located in an angiographically diffusely diseased segment. Procedural success rate was 100% without any periprocedural myocardial infarction. After a mean follow-up of 407.33+/-53 (range: 344-498) days the overall MACE-free survival was 95.2%. Freedom from target revascularization was 95.2%.


CONCLUSIONS
The result of this non-randomized observational study suggests that the implantation of PES for de novo, non-significant lesions appears most probably safe and effective.
Rodriguez-Granillo
Gastón
G
Erasmus Medical Center, Thoraxcenter, Rotterdam, Netherlands.
Valgimigli
Marco
M
Ong
Andrew T L
AT
Aoki
Jiro
J
van Mieghem
Carlos A G
CA
Hoye
Angela
A
Tsuchida
Keiichi
K
McFadden
Eugene
E
de Feyter
Pim
P
Serruys
Patrick W
PW
D000368:Aged; D017023:Coronary Angiography; D003324:Coronary Artery Disease / Q000000981:diagnostic imaging / Q000628:therapy*; D023903:Coronary Restenosis / Q000517:prevention & control*; D005260:Female; D006801:Humans; D008297:Male; D017239:Paclitaxel / Q000008:administration & dosage*; D015607:Stents
D017239:Paclitaxel